•  

Partnerships

LAB150 launches new immuno-oncology project from Sunnybrook Research Institute

Toronto, Ontario, June 04, 2020 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP) announced today the launch of a new LAB150 project aimed at developing a novel therapeutic agent for immuno-oncology. The research for the promising new approach comes from Dr. Jean Gariépy and his lab at Sunnybrook Research Institute, a TIAP Member institution. The last several years has seen the introduction of a new blockbuster class of drugs for treating cancers – specifically, the immune checkpoint inhibitors (ICIs). These drugs act ... Read more

Funding for Sinai Health Netherton Syndrome project from partners AmorChem and Evotec

TORONTO, May 12, 2020 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP), Evotec SE and AmorChem II Fund L.P. (AmorChem) are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide. The project was initiated in partnership with a group of scientists from Sinai Health’s Lunenfeld-Tanenbaum Research Institute (LTRI) in Toronto, Canada and focuses on a specific group of enzymes called tissue kallikreins. These proteins ... Read more

Zucara Therapeutics Announces US$21M Series A Financing

– Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials – – Series A Financing led by the Perceptive Xontogeny Venture Fund  – TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”). The proceeds from the financing will fund Phase 1 and ... Read more

Fibrocor and Galapagos Sign Expanded Collaboration in Fibrosis

Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel targets in fibrosis, with Galapagos taking an equity stake in Fibrocor. Fibrocor is a privately held Canadian company specializing in the development of tissue-specific therapeutics to treat fibrotic diseases of the kidney, liver, lung and other organs. To date, the company has successfully identified a suite of novel targets in fibrosis through ... Read more

Allogene Therapeutics enters collaboration with Notch Therapeutics

Collaboration Includes Exclusive Rights and Targets for Initial Applications in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus Development and Commercial Milestones and Royalties on Net Sales SOUTH SAN FRANCISCO, Calif. and TORONTO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Notch Therapeutics Inc., an immune cell therapy company creating universally compatible, allogeneic ... Read more

Notch Therapeutics, a new company in the field of gene-modified T cell therapy

Toronto, ON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that creates allogeneic (donor) gene-edited T cells from stem cells on an industrial scale, efficiently making T cell therapies that are clinically robust and of a consistently high quality. Notch is actively pursuing industry partnerships. The founders of Notch - Sunnybrook Health Sciences Centre, University of Toronto (UoT), Toronto Innovation Acceleration Partners (TIAP) ... Read more

BetaKit Article on Amgen Partnership

Jessica Galang of BetaKit, a Canadian online publication on start-up news and tech innovation, writes about TIAP's recently announced strategic partnership with Amgen.  Read more here: http://bit.ly/2lSDVYE   Read more

TIAP Announces Strategic Partnership with Amgen

Toronto, Ontario, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP – formerly MaRS Innovation), a leading member-based Canadian provider of venture builder expertise in the early-stage health science field, is pleased to announce the establishment of a collaboration with Amgen, a global leader in the biotechnology industry. Under the terms of the agreement, Amgen and TIAP will jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member institutions. The two organizations will collaborate in a proactive ... Read more

Zucara Therapeutics Secures Grant from GlycoNet

Toronto & Vancouver, Canada:  Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with type 1 diabetes and other types of insulin-dependent diabetes, has secured a grant of $69,000 from Canadian Glycomics Network (GlycoNet) to expand and validate the model for its lead drug candidate “ZT-01” from type 1 diabetes (T1D) to type 2 diabetes (T2D). Zucara Therapeutics will match the funding with an additional $85,000 in cash and in-kind contributions, including scientific ... Read more

LAB150 adds project with focus on mental health

Toronto, ON, June 11, 2019 (GLOBE NEWSWIRE) -- It is estimated that 5% of the global population is affected by Major Depressive Disorder (MDD) at any given time. While there are many antidepressant drugs on the market, most of these drugs need weeks to take effect, if at all. This exciting new project hopes to develop a novel rapid-acting antidepressant that has the potential to provide patient relief much faster than conventional treatments. The project builds on years of research led by Dr. ... Read more
Page 1 of 1612345...10...Last »